EVH Earnings

EVH reported its earnings on 2026-02-24, showcasing a revenue of 468.72M against an estimate of 469.22M, resulting in a -0.11% surprise. The EPS was 0.08, surpassing the expected 0.05 by 60%. The stock experienced a 22.66% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following EVH's earnings announcement on 2026-02-24, the stock price moved by 22.66% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, EVH's stock price tends to shift by an average of 2.91% in the 10 days leading up to earnings and -2.37% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate EVH's annual revenue to reach 547.31M, while the EPS is projected at 0.05. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between EVH's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EVH's stock price typically moves by 2.91% in the 10 days before its earnings and -2.37% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.05 and revenue of 547.31M.

Evolent's earnings call reveals strong revenue growth projections driven by new contracts, including a significant partnership with Blue Cross, and enhanced margin protections. While there are concerns about membership declines in certain segments, the optimistic guidance, strategic deleveraging, and AI-driven efficiency improvements are positive indicators. The Q&A section further supports confidence in the company's conservative financial approach and potential growth in oncology. Despite some uncertainties, the overall sentiment suggests a positive stock price movement.